Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A Phase 1, Double Blind, Randomized, Placebo-Controlled, Multi-Center, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2693 in Patients with Non-Alcoholic Steatohepatitis (NASH) with Fibrosis Stage 0-3 and Carriers of the PNPLA3 148M Risk Allele

The purpose of this voluntary research study is to test the safety and ability to tolerate of the an injection treatment of the study drug AZD2693 in patients with Non-alcoholic Steatohepatitis (NASH).

If you enroll in this study, you will undergo a series of testing. You will be asked to complete an initial assessment that includes a physical exam, height, and weight measurements, an electrocardiogram, questionnaires, COVID-19 screening and test, an MRI, a liver biopsy, an elastography, telemetry, blood draws, urine drug testing and a pregnancy test if applicable. For treatment, you will be asked to administer study drug or placebo (a substance that has no therapeutic effect) at week 1, week 5 and week 9. There will be 13 other study visits that will occur biweekly.


Jonathan Stine
Gloriany Rivas - at or 717-531-0003, ext=320223

18 year(s) or older
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
BMI within the range 25 to 45 kg/m2
NASH diagnosis

Exclusion Criteria:
history of liver transplant
pre-existing renal disease
Digestive Systems & Liver Disease
I'm interested
Share via email
See this study on
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,